Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.
Vertex Pharmaceuticals beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its blockbuster cystic fibrosis treatments. Vertex tops Q1 profit estimates on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback